

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
22 August 2024 (22.08.2024)



(10) International Publication Number
WO 2024/168386 A1

(51) International Patent Classification:

A61K 51/08 (2006.01) A61K 47/12 (2006.01)
A61K 9/00 (2006.01) A61K 47/54 (2017.01)
A61K 9/08 (2006.01) A61K 47/65 (2017.01)
A61K 47/02 (2006.01)

LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(21) International Application Number:

PCT/AU2024/050097

(22) International Filing Date:

14 February 2024 (14.02.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2023900356 14 February 2023 (14.02.2023) AU

(71) Applicant: **CLARITY PHARMACEUTICALS LIMITED** [AU/AU]; 4 Cornwallis Street, Eveleigh, New South Wales 2015 (AU).

(72) Inventors: **LENGYELOVA, Eva**; C/- Clarity Pharmaceuticals Limited, National Innovation Centre, 4 Cornwallis Street, Eveleigh, New South Wales 2015 (AU). **MILLER, Robert**; C/- Clarity Pharmaceuticals Limited, National Innovation Centre, 4 Cornwallis Street, Eveleigh, New South Wales 2015 (AU). **EMMETT, Louise**; C/- Clarity Pharmaceuticals Limited, National Innovation Centre, 4 Cornwallis Street, Eveleigh, New South Wales 2015 (AU).

(74) Agent: **DAVIES COLLISON CAVE PTY LTD**; Level 4, 7 Macquarie Place, Sydney, New South Wales 2000 (AU).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,

(54) Title: METHODS FOR THE DETECTION AND DIAGNOSIS OF CANCERS ASSOCIATED WITH OVEREXPRESSION OF A PSMA RECEPTOR

(57) Abstract: The present invention relates to methods for the detection and diagnosis of a cancer related to overexpression of prostate-specific membrane antigen (PSMA) by administering a dose of between about 100MBq to about 300 MBq of a 64Cu-labelled sarcophagine compound, Sar-bisPSMA, and PET imaging the patient. This method allows for images of greater resolution, even at cancer sites having a lower density of PSMA, such as a secondary lesion.

WO 2024/168386 A1